Hyundai Pharm (004310) - Net Assets

Latest as of February 2026: ₩134.81 Billion KRW ≈ $91.36 Million USD

Based on the latest financial reports, Hyundai Pharm (004310) has net assets worth ₩134.81 Billion KRW (≈ $91.36 Million USD) as of February 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩224.31 Billion ≈ $152.01 Million USD) and total liabilities (₩89.49 Billion ≈ $60.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hyundai Pharm (004310) tangible net worth to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩134.81 Billion
% of Total Assets	60.1%
Annual Growth Rate	-0.79%
5-Year Change	-5.19%
10-Year Change	-17.96%
Growth Volatility	7.25

Hyundai Pharm - Net Assets Trend (2010–2025)

This chart illustrates how Hyundai Pharm's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Hyundai Pharm to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Hyundai Pharm (2010–2025)

The table below shows the annual net assets of Hyundai Pharm from 2010 to 2025. For live valuation and market cap data, see 004310 market cap.

Year	Net Assets	Change
2025-11-30	₩82.10 Billion ≈ $55.64 Million	+3.83%
2024-11-30	₩79.07 Billion ≈ $53.59 Million	-6.60%
2023-11-30	₩84.66 Billion ≈ $57.37 Million	-2.19%
2022-11-30	₩86.56 Billion ≈ $58.66 Million	-0.05%
2021-11-30	₩86.60 Billion ≈ $58.69 Million	-3.93%
2020-11-30	₩90.14 Billion ≈ $61.09 Million	+2.92%
2019-11-30	₩87.58 Billion ≈ $59.35 Million	-18.15%
2018-11-30	₩107.00 Billion ≈ $72.52 Million	+9.08%
2017-11-30	₩98.10 Billion ≈ $66.48 Million	-1.98%
2016-11-30	₩100.08 Billion ≈ $67.82 Million	-1.12%
2013-11-30	₩101.21 Billion ≈ $68.59 Million	+1.53%
2012-11-30	₩99.69 Billion ≈ $67.56 Million	-4.44%
2011-11-30	₩104.32 Billion ≈ $70.69 Million	+12.77%
2010-11-30	₩92.50 Billion ≈ $62.69 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Hyundai Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 21.9% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (November 2025)

Component	Amount	Percentage
Retained Earnings	₩53.43 Billion	65.07%
Other Components	₩28.68 Billion	34.93%
Total Equity	₩82.10 Billion	100.00%

Hyundai Pharm Competitors by Market Cap

The table below lists competitors of Hyundai Pharm ranked by their market capitalization.

Company	Market Cap
Currency Exchange International Corp TO:CXI	$120.10 Million
Waton Financial Limited Ordinary Shares NASDAQ:WTF	$120.11 Million
Arihant Superstructures Limited NSE:ARIHANTSUP	$120.11 Million
Lam Soon (Thailand) Public Company Limited BK:LST	$120.13 Million
Monte Carlo Fashions Limited NSE:MONTECARLO	$120.01 Million
Servotronics Inc NYSE MKT:SVT	$120.00 Million
vTv Therapeutics Inc NASDAQ:VTVT	$119.97 Million
Ba Ria Vung Tau House Development JSC VN:HDC	$119.94 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hyundai Pharm's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 79,074,176,370 to 82,103,210,700, a change of 3,029,034,330 (3.8%).
Net income of 2,516,256,240 contributed positively to equity growth.
Dividend payments of 783,724,140 reduced retained earnings.
Other factors increased equity by 1,296,502,230.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩2.52 Billion	+3.06%
Dividends Paid	₩783.72 Million	-0.95%
Other Changes	₩1.30 Billion	+1.58%
Total Change	₩-	3.83%

Book Value vs Market Value Analysis

This analysis compares Hyundai Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.82x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 1.38x to 1.82x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-11-30	₩4159.65	₩5730.00	x
2018-11-30	₩3907.97	₩5730.00	x
2019-11-30	₩3244.92	₩5730.00	x
2020-11-30	₩3233.36	₩5730.00	x
2021-11-30	₩3106.36	₩5730.00	x
2022-11-30	₩3143.63	₩5730.00	x
2023-11-30	₩3174.38	₩5730.00	x
2024-11-30	₩3025.52	₩5730.00	x
2025-11-30	₩3141.42	₩5730.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hyundai Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 3.06%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 1.31%
• Asset Turnover: 1.18x
• Equity Multiplier: 1.99x
Recent ROE (3.06%) is above the historical average (0.95%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2010	3.21%	2.65%	0.85x	1.42x	₩-6.28 Billion
2011	0.50%	0.46%	0.73x	1.51x	₩-9.87 Billion
2012	-4.89%	-4.74%	0.68x	1.51x	₩-14.77 Billion
2013	1.40%	1.31%	0.75x	1.42x	₩-8.66 Billion
2016	1.26%	1.05%	0.80x	1.50x	₩-8.75 Billion
2017	1.49%	1.12%	0.84x	1.58x	₩-8.35 Billion
2018	0.87%	0.69%	0.84x	1.48x	₩-9.77 Billion
2019	1.32%	0.86%	0.93x	1.66x	₩-7.60 Billion
2020	2.43%	1.64%	0.84x	1.75x	₩-6.83 Billion
2021	-3.66%	-2.27%	0.85x	1.89x	₩-11.83 Billion
2022	-0.19%	-0.10%	0.90x	2.09x	₩-8.82 Billion
2023	7.23%	3.39%	1.17x	1.83x	₩-2.34 Billion
2024	-0.73%	-0.33%	1.12x	1.98x	₩-8.48 Billion
2025	3.06%	1.31%	1.18x	1.99x	₩-5.69 Billion

Industry Comparison

This section compares Hyundai Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $437,190,715,767
Average return on equity (ROE) among peers: 2.19%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hyundai Pharm (004310)	₩134.81 Billion	3.21%	0.66x	$120.05 Million
Dongwha Pharm.Co.Ltd (000020)	$229.73 Billion	2.15%	0.36x	$100.12 Million
Yuhan Corp. (000100)	$1.28 Trillion	6.99%	0.27x	$3.85 Billion
Yuhan Corp Preferred (000105)	$2.01 Trillion	4.74%	0.23x	$49.81 Million
Yuyu Pharma (000220)	$86.87 Billion	4.63%	0.56x	$43.43 Million
Yuyu Pharma Inc (000225)	$123.37 Billion	-4.85%	0.58x	$15.35 Million
Yuyu Pharma Inc (000227)	$90.54 Billion	5.22%	0.52x	$42.17 Million
Ildong Holdings Co Ltd (000230)	$105.71 Billion	13.32%	1.07x	$55.25 Million
Samil Pharm (000520)	$55.42 Billion	-20.19%	0.95x	$104.45 Million
Donga Socio Holdings (000640)	$208.05 Billion	10.39%	1.63x	$358.21 Million
Jw Pharmac (001060)	$188.54 Billion	-0.51%	2.36x	$413.36 Million

About Hyundai Pharm

KO:004310 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$120.05 Million

₩177.15 Billion KRW

Market Cap Rank

#18577 Global

#856 in Korea

Share Price

₩5730.00

Change (1 day)

+0.00%

52-Week Range

₩3415.00 - ₩14340.00

All Time High

₩14340.00